Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a prospective, single arm, single center, phase II study of NALIRIFOX as conversion therapy in patients with locally advanced pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years old, ≤ 70 years old, male or female; 2. Understand the objectives and benefits and risks of the clinical trial, voluntarily participate in and sign the informed consent form; 3. ECOG score 0-1; 4. The subject had histopathologically or cytologically confirmed type of pancreatic ductal adenocarcinoma 5. Local progression according to the 2022 CSCO guidelines; 6. Initial subjects with locally advanced pancreatic cancer who have not undergone resection of pancreatic tumor (except open exploration or internal drainage surgery), chemotherapy, targeted, or immunotherapy. 7. At least one measurable pancreatic lesion per RECIST 1.1 criteria; 8. Expected survival time ≥ 3 months. 9. Heart, lung, liver, kidney and other major organ functions are basically normal. 10. Hematology tests should meet the following criteria (no blood transfusion, no use of blood products, granulocyte colony-stimulating factor, or other hematopoietic growth factors within 7 days pr